CliffBio
small molecule

FENTANYL CITRATE

FENTANYL CITRATE

Loss of exclusivity—loss of exclusivity
CompanyPar →See this company's full patent-cliff portfolio

Drug detail

Brand nameFENTANYL CITRATE
Active ingredientFENTANYL CITRATE
StrengthEQ 1.6MG BASE
Dosage formTROCHE/LOZENGE
RouteTRANSMUCOSAL
ModalitySmall molecule
FDA approvalOctober 2009
Marketing statusDISCN

More from Par

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

FENTANYL CITRATE patent cliff — loss of exclusivity — | CliffBio